Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vusolimogene oderparepvec-wtpg
- Development stage
- Approved
- Lead developer
- Replimune
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intratumoral
01
Overview
Tudriqev (vusolimogene oderparepvec-wtpg) is a genetically modified oncolytic viral therapy based on a proprietary strain of herpes simplex virus type 1 (HSV-1). Developed by Replimune, it is engineered to selectively replicate in tumor cells, leading to direct oncolysis and the induction of a systemic anti-tumor immune response. The virus is modified by the deletion of the ICP34.5 and ICP47 genes to enhance tumor selectivity and antigen presentation, and it is armed with transgenes for a fusogenic protein (GALV-GP R⁻) to increase cell killing and GM-CSF to stimulate dendritic cell activity. It is indicated for the treatment of adult patients with unresectable advanced cutaneous melanoma who have progressed on PD-1-blocking therapies, typically administered via intratumoral injection in combination with nivolumab.
- Brand names
- Tudriqev
- Other names
- vusolimogene oderparepvec
02
Targets
GM-CSF (Granulocyte-macrophage colony-stimulating factor)Gibbon ape leukemia virus fusogenic membrane glycoprotein (GALV-GP R-)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)
Beyond the preview
Go deeper on vusolimogene oderparepvec-wtpg.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vusolimogene oderparepvec-wtpg.